Recently added Catalysts

Upcoming Catalyst

Drug Pipeline Intelligence

Clinical Trial Results

Inside Trades

Options Data

News Section

Hedge Funds

Ownership Trends

Competitive Position

Oncolytics Biotech Inc.

$0.84

0 (+0.12%)

D 36Pipeline Score Overvalued Biotech · Clinical

Market Cap

100.75 M

EPS

-0.32

P/E Ratio

Value Trade

637.71 K

-0.08 %

Week

5.5 %

1 Month

4.17 %

3 Month

-25.3 %

6 Month

-73.55 %

5 Year

-98.38 %

All Time

Cash Data

Cash Position
-
Monthly Burn
-
Runway
-

Overview

Volume

488.77 K

52 Week Range

0.73 - 1.51

% held by Insiders

1.83 %

% held by Institutions

4.35 %

Enterprise Value

96.63 M

Total Shares

119.35 M

Short %

8.35 %

Float Shares

111.97 M

Company Description

HQ: SUITE 325, 4350 EXECUTIVE DRIV...

Employees:29

https://www.oncolyticsbiotech....

locked

Upcoming Catalyst

Catalyst	Drug/Treatment	Stage	Probability of Approval	Description	Drug Type	Therapeutic Area
Phase 2 data readout example	pelareorep Metastatic breast cancer — randomized Phase 2 programs (pelareorep combinations) Fast Track	Phase 2	—	Subscribe to access the data.	Oncolytic Viruses	Oncology
Phase 2 data readout example	pelareorep Metastatic breast cancer — randomized Phase 2 programs (pelareorep combinations) Fast Track	Phase 2	—	Subscribe to access the data.	Oncolytic Viruses	Oncology
Phase 2 data readout example	pelareorep Metastatic breast cancer — randomized Phase 2 programs (pelareorep combinations) Fast Track	Phase 2	—	Subscribe to access the data.	Oncolytic Viruses	Oncology

Unlock Upcoming Catalyst data

Catalyst Timeline

Dated clinical, regulatory & corporate events for Oncolytics Biotech Inc.

972Total events

7Upcoming

151Tier-1 (high impact)

2008 – 2027Coverage

Upcoming catalysts 2

TBD

T2Enrollment Complete

Subscribe to view catalyst details

Pelareorep

TBD

T2Timing Guidance

Subscribe to view catalyst details

Pelareorep

Event history 2

TBD

▲FDA Feedback ReceivedPelareorepFDA Meeting

Subscribe to view catalyst details

TBD

◆Type D MeetingPelareorepFDA Meeting

Subscribe to view catalyst details

Unlock the full Catalyst Timeline

Past FDA Catalysts & PDUFA Decisions

Date	Drug	Catalyst	Stage	Outcome	Reaction	Event Move %	Best Trade %
2025-12-31	pelareorep	phase 2 data readout	Phase 2	—	–	–	–
2025-12-31	pelareorep	phase 2 data readout	Phase 2	—	–	–	–
2025-12-31	pelareorep	phase 2 data readout	Phase 2	—	–	–	–

Unlock 2 more historical catalysts

Drug Pipeline Intelligence

D36

Pipeline Score

$27M

Pipeline Value

Overvalued

Valuation Signal

Drugs Scored

0.3x

rNPV / MCap

Top 53%

Micro Cap

(rank 440 of 933)

Percentile Rank

Oncolytics Biotech Inc. faces pipeline headwinds (36/100), with $1.7B risk-adjusted pipeline value, led by Reolysin in Metastatic Breast Cancer (Phase 2), across $79B in total addressable markets, but cash runway is a concern.

Showing 1 of 1 assets

Drug	Indication	Phase	NCT ID	PTRS	rNPV	Status	Enrollment	Velocity	Design	Completion	ML Signal	Last Change
REOLYSIN Monoclonal antibody	Carcinoma, Squamous Cell of the Head and Neck	Phase 3	NCT00753038	48%	$943M	COMPLETED	181	-	-	May 1, 2013	-	Nov 4, 2014

Unlock Drug Pipeline Intelligence

Clinical Trial Results

Drug Name	Indications	Phase	Date	Trial Results Summary	Title
pelareorep Fast TrackAcceleratedOrphan	unresectable metastatic squamous cell carcinoma of the anal canal	—	2026-04-27	median duration of response of 15.5 months versus 9.5 months; 12-month survival of 82% versus 45.7% Read More	Oncolytics Aligns with FDA on Planned Pivotal Anal Cancer Study Read More
pelareorep Fast TrackAcceleratedOrphan	unresectable metastatic squamous cell carcinoma of the anal canal	—	2026-04-27	median duration of response of 15.5 months versus 9.5 months; 12-month survival of 82% versus 45.7% Read More	Oncolytics Aligns with FDA on Planned Pivotal Anal Cancer Study Read More
pelareorep Fast TrackAcceleratedOrphan	unresectable metastatic squamous cell carcinoma of the anal canal	—	2026-04-27	median duration of response of 15.5 months versus 9.5 months; 12-month survival of 82% versus 45.7% Read More	Oncolytics Aligns with FDA on Planned Pivotal Anal Cancer Study Read More

Unlock Clinical Trial Results data

Inside Trades

YEARLY INSIDER TRANSACTIONS

Sector Avg.

INSIDERS
SOLDINSIDERS
BOUGHT

POSITIVE SENTIMENT Based on 22 Insiders Transactions

Unlock Inside Trades data

Show Data

Hedge Funds

Shares Held

2040.00B1530.00B1020.00B510.00B0

Q3
2024

Q4
2024

Q1
2025

Q2
2025

HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT

POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter

18 buying (3 new)·9 selling (1 exited)·2 unchanged

Fund Count

60%

Share Volume

25%

Conviction

15%

Hedge Funds invested in ONCY

HedgeFund Name ( 3 )	% of Portfolio	Current MV -	Shares Owned -
Example Capital Management	2.5 %	15.00 M	250.00 K
Example Capital Management	2.5 %	15.00 M	250.00 K
Example Capital Management	2.5 %	15.00 M	250.00 K

Unlock Hedge Funds table data

ONCY Institutional Ownership Trends

Current Insider %

5.20%

—+0.00%

Current Institutional %

62.40%

—+0.00%

Total Ownership

67.60%

Insider + Institutional

Data Points

1 Ticker(s)

Option Chain Statistics

Expiration	Volume			Open Interest			Implied Volatility Calls			Implied Volatility Puts
Expiration	Calls	Puts	Put-Call Ratio	Calls	Puts	Put-Call Ratio	IV	OiWaIv	VWaIv	IV	OiWaIv	VWaIv

Unlock Option Chain Statistics data

Option Chain

Calls			Strike	Puts
Last Price	Volume	Open Interest	Strike	Last Price	Volume	Open Interest
No data available

Unlock Option Chain data

Unlock Options Chart data

Open interest

Today's Open Interest

1.00 M

Put-Call Ratio

1.1

Put Open Interest

480.00 K

Call Open Interest

520.00 K

Open Interest Avg (30-day)

900,000

Today vs Open Interest Avg (30-day)

11.11%

Option Volume

Today's Volume

750.00 K

Put-Call Ratio

0.95

Put Volume

360.00 K

Call Volume

390.00 K

Volume Avg (30-day)

800,000

Today vs Volume Avg (30-day)

-6.25%

Oncolytics Biotech has reported significant progress in its REO 033 trial for RAS-mutant MSS colorectal cancer, with half of the planned clinical sites set to activate this month. The company plans to hold a Type D meeting with the FDA to discuss a potential registrational pathway for the trial. The study aims to validate previous encouraging results and has received Fast Track designation from the FDA.

Oncolytics Biotech® Secures New U.S. Patent Protecting Commercial Manufacturing of Pelareorep into 2044

Oncolytics Biotech has secured a new U.S. patent protecting the manufacturing process of its investigational immunotherapy, pelareorep, until 2044. This patent enhances the company's intellectual property portfolio and supports the commercial production of pelareorep. Additionally, a method-of-use patent application is under review, potentially extending protection to 2046. Oncolytics plans further patent filings to broaden its intellectual property estate.

Oncolytics Biotech® Announces Appointment of Steve Glover to Board of Directors and Promotion of John McAdory to Chief Operating Officer

Oncolytics Biotech has appointed Steve Glover to its Board of Directors and promoted John McAdory to Chief Operating Officer. Glover brings extensive experience from his previous role at Ambrx Biopharma, while McAdory will oversee clinical operations and development. The company is focused on advancing its investigational immunotherapy, pelareorep, which shows promise in treating various cancers.

-ONCY

Jun 1, 2026

ONCYPhases

Oncolytics Biotech has announced alignment with the FDA on a pivotal clinical study for pelareorep, aimed at treating unresectable metastatic squamous cell carcinoma of the anal canal. The study will focus on patients with no FDA-approved therapies and aims to support both accelerated and full approval. The company plans to incorporate FDA feedback into the final protocol, emphasizing the need for new treatment options in this area.

-ONCY

Apr 6, 2026

ONCYFDA Updates

Oncolytics Biotech® Announces Type C FDA Meeting to Discuss Single-arm Registrational Pathway for Pelareorep in Anal Cancer

Oncolytics Biotech has announced a Type C meeting with the FDA to discuss a registrational pathway for pelareorep in anal cancer. The focus will be on initiating a pivotal study evaluating pelareorep in combination with a checkpoint inhibitor for patients with squamous cell anal carcinoma. Encouraging clinical activity has been observed, with a notable objective response rate in previous studies.

-ONCY

Apr 1, 2026

ONCYGeneral

▲ +9.6%on this newsshared move

Oncolytics Biotech® Completes Domicile Change to the United States

Oncolytics Biotech has successfully changed its jurisdiction of incorporation from Alberta, Canada, to Nevada, USA. This transition, approved by shareholders, is expected to enhance operational efficiency and access to U.S. capital markets. The company will maintain its Calgary office while establishing a new headquarters in San Diego. The change reflects Oncolytics' status as a U.S. domestic issuer.

-ONCY

Mar 19, 2026

ONCYConferences/Events

Oncolytics Biotech to Present New Mechanistic and Translational Data Supporting Pelareorep as an Immune-Priming Backbone at AACR 2026

Oncolytics Biotech Inc. announced that two abstracts related to its investigational immunotherapy pelareorep were accepted for presentation at the AACR Annual Meeting 2026. Pelareorep has shown promising results in activating immune responses in various cancers, particularly those driven by RAS mutations. Key data indicate that pelareorep could significantly enhance the effectiveness of immunotherapy and targeted therapies. The company aims to advance its clinical programs to address significant unmet needs in oncology, including pancreatic cancer.

Oncolytics Biotech has received FDA Fast Track Designation for pelareorep in combination with bevacizumab and FOLFIRI for treating KRAS-mutant MSS metastatic colorectal cancer. Clinical data shows a 33% objective response rate and improved survival metrics compared to standard-of-care. The company plans to initiate a controlled study with interim data expected by the end of 2026.

-ONCY

Jan 16, 2026

ONCYGeneral

Oncolytics Biotech® Announces Results of Special Meeting of Shareholders

Oncolytics Biotech announced the results of its Special Meeting of Shareholders, where all proposed resolutions were approved. This includes the company's transition from Alberta to British Columbia and then to Nevada, as well as the implementation of the 2026 Incentive Award Plan. The company anticipates these changes will enhance its operational efficiency and regulatory standing.

-ONCY

Jan 15, 2026

ONCYGeneral

▼ -7.3%on this newsshared move

Oncolytics Biotech® Appoints John McAdory as EVP of Strategy and Operations and Yujun Wu to Lead Biostatistics

Oncolytics Biotech has appointed John McAdory as EVP of Strategy and Operations and Yujun Wu as VP of Biostatistics. These appointments aim to enhance the company's operational and regulatory capabilities as it advances registration-directed programs in gastrointestinal cancers. McAdory's experience in late-stage oncology trials and Wu's statistical expertise are expected to support Oncolytics' strategic focus on efficient drug development.

-ONCY

Jan 13, 2026

ONCYPhases

Oncolytics Biotech® Announces Updated Clinical Data from GOBLET Cohort 4 Demonstrating Activity of Pelareorep Plus Atezolizumab in Third-Line Anal Cancer

Oncolytics Biotech has announced updated clinical data from GOBLET Cohort 4, showing that the combination of pelareorep and atezolizumab achieved a 29% objective response rate in third-line anal cancer patients. The median duration of response was nearly 17 months, suggesting significant clinical benefit in a heavily pretreated population. The company plans to discuss a registration study with the FDA in early 2026.

-ONCY

Jan 9, 2026

ONCYGeneral

Oncolytics Biotech® Outlines Strategic Rationale for Proposal to Change Jurisdiction of Incorporation to Nevada

Oncolytics Biotech Inc. plans to change its jurisdiction of incorporation from Alberta, Canada, to Nevada, USA, to better align with its U.S.-focused operations. This move aims to simplify regulatory complexities and enhance access to U.S. capital markets. The proposal is subject to shareholder approval at a special meeting scheduled for January 15, 2026.

-ONCY

Jan 9, 2026

ONCYGeneral

Oncolytics Biotech® Provides Update on Intellectual Property Strategy and Patent Filings

Oncolytics Biotech has provided an update on its intellectual property strategy, focusing on extending patent protection for its immunotherapy drug, pelareorep. The company filed a prioritized examination patent application with the USPTO, which could extend patent claims to 2044. Additionally, Oncolytics plans to file more applications to cover novel uses of pelareorep, aiming to enhance its commercial potential.

Oncolytics Biotech has provided updated clinical safety data for pelareorep, demonstrating its favorable safety profile in over 300 gastrointestinal cancer patients. The drug has been administered to more than 1,200 patients and shows potential as a platform therapy. Despite some adverse events, the overall safety data supports its advancement in clinical studies.

-ONCY

Aug 28, 2025

ONCYConferences/Events

Oncolytics Biotech® has announced plans to engage the FDA for a potential registration-enabled pivotal study in first-line metastatic pancreatic ductal adenocarcinoma (mPDAC). The company is optimistic about pelareorep's mechanisms and the positive survival data observed in previous studies. If negotiations with the FDA proceed smoothly, trial activities are expected to start by the end of 2025. Oncolytics sees this as a critical step towards enhancing shareholder value and attracting pharmaceutical partnerships in the field of immunotherapy.

-ONCY

Jul 23, 2025

ONCYConferences/Events

Oncolytics Biotech Inc. has revealed compelling clinical data on its oncolytic virus therapy, pelareorep, showcasing a significant survival benefit in patients with metastatic pancreatic ductal adenocarcinoma and breast cancer. The company plans to advance pelareorep into registration-enabling trials, emphasizing its strong efficacy signals and favorable safety profile demonstrated across over 1,100 patients. These findings position pelareorep as a potential innovator in immunotherapy, particularly for tumors traditionally considered resistant to such treatments. Additionally, the therapy has received fast-track designations from the FDA, signaling an expedited path toward potential approval.

-ONCY

Jun 30, 2025

ONCYGeneral

Oncolytics Biotech® Appoints Former Ambrx Executive as Chief Business Officer to Drive Business Development Strategy

Oncolytics Biotech has appointed Andrew Aromando as Chief Business Officer to lead its global business development strategy. Aromando brings extensive experience from Ambrx Biopharma, where he played a key role in a significant acquisition. His primary focus will be to optimize the value of Oncolytics' pelareorep, which shows promise in treating various cancers. The company's CEO expressed confidence in Aromando's ability to enhance clinical and business strategies amid ongoing development efforts.

-ONCY

Jun 11, 2025

ONCYGeneral

▲ +34.1%on this news· ran to +50% by day 3

Oncolytics Biotech® Names New CEO to Accelerate Momentum in Immunotherapy Programs

Oncolytics Biotech has appointed Jared Kelly as its new CEO to enhance the development of its immunotherapy programs, particularly focusing on pelareorep, which has shown promising clinical results. Kelly's extensive experience in biotech and successful corporate strategies is expected to drive the company's goals of advancing pelareorep's clinical development and securing partnerships. The immunotherapeutic agent has received FDA Fast Track designation for its indications and has demonstrated notable efficacy in recent trials, indicating its potential in oncology treatment.

-ONCY

May 23, 2025

ONCYConferences/Events

Oncolytics Biotech® to Present New Clinical Trial Data at ASCO Showing Pelareorep

Oncolytics Biotech Inc. presented positive clinical trial data regarding pelareorep at the 2025 ASCO Annual Meeting. The Phase I/II GOBLET trial's findings suggest that pelareorep successfully primes the tumor microenvironment, enhancing immune responses and allowing tumor-infiltrating lymphocytes to target pancreatic tumors. The trial demonstrated a 62% overall response rate and highlighted the importance of pre-existing tumor-infiltrating lymphocytes. This data could pave the way for further combination therapies in treating advanced cancers.

-ONCY

May 14, 2025

ONCYGeneral

FIRST QUARTER INTERIM FINANCIAL STATEMENT Document Condensed Interim Consolidated Financial Statements (unaudited) Oncolytics Biotech Inc. For the three months ended

Oncolytics Biotech Inc. reported its financial results for the first quarter of 2025, indicating a net loss of $6,687, which is a slight improvement from the loss of $6,894 in the same quarter the previous year. The company has an accumulated deficit of $484,400, and its total assets decreased to $19,702 compared to $20,187 at the end of 2024. Despite raising $6,228 through a share issuance, there are substantial doubts concerning the company's ability to sustain operations without additional financing. Oncolytics is focused on advancing its cancer treatment, pelareorep, but continues to face challenges in achieving profitability.

-ONCY

May 14, 2025

ONCYGeneral

Oncolytics Biotech® Reports First Quarter Financial Results and Highlights Clinical Momentum

Oncolytics Biotech reported significant advancements in their ongoing clinical trials for pelareorep, particularly in breast, anal, and pancreatic cancers. Their first quarter financial results showed a stable cash position, with $15.3 million available to support further development. The company highlighted promising efficacy data and was recognized for its potential to enhance patient outcomes in difficult-to-treat cancer indications. Upcoming presentations at notable oncology conferences, alongside a substantial share purchase agreement, position Oncolytics for continued growth and innovation in cancer treatment.

Oncolytics Biotech® Reports Highlights and Financial Results for Q4 and Year-End 2024

Oncolytics Biotech Inc. reported its financial results for Q4 and year-end 2024, highlighting significant advances in its lead candidate, pelareorep, showing strong efficacy signals across multiple oncology indications. The company surpassed expectations in clinical trials for HR+/HER2- metastatic breast cancer, pancreatic cancer, and anal cancer. While the cash position is $15.9 million, allowing operations through key milestones, the company experienced a significant increase in net loss compared to the previous year, drawing attention to financial health. Management plans to host a conference call to outline future strategies and milestones for 2025.

-ONCY

Feb 19, 2025

ONCYPhases

Oncolytics Biotech® Advances Key Pancreatic and Anal Cancer Trials, Strengthening Pipeline in 2025

Oncolytics Biotech Inc. has announced significant regulatory and clinical advancements for its immunotherapy pelareorep, particularly focusing on pancreatic and anal cancers. The German regulatory authority has approved the continuation of patient enrollment in its pancreatic cancer trial, which signifies a positive safety evaluation. Additionally, new data presented at the ASCO GI 2025 underscores pelareorep's potential efficacy when combined with existing treatment regimens. The company anticipates more data readouts and interactions with regulatory bodies in 2025, which may accelerate clinical trials and registration processes for this innovative therapy.

-ONCY

Feb 18, 2025

ONCYPhases

Oncolytics Biotech Inc. will host a conference call on November 12, 2024, at 8:30 a.m. ET to discuss its third quarter financial results and recent operational highlights. The company, focused on developing pelareorep, an immunotherapeutic agent, has shown promising results in clinical studies involving metastatic breast and pancreatic cancers. This call offers stakeholders insight into the company's progress and future plans.

Oncolytics Biotech Inc. has announced a preliminary collaboration with the Global Coalition for Adaptive Research (GCAR) for evaluating pelareorep in a master protocol aimed at treating metastatic pancreatic ductal adenocarcinoma. This initiative seeks to finalize a seamless Phase 2/3 trial design that will study multiple therapies, aiming for expedited data that could support regulatory approval. The collaboration is viewed positively by the leadership of both organizations, who are optimistic about the insights from previous success rates and hope to drive quicker advancements in treatment for pancreatic cancer.

FIRST QUARTER INTERIM FINANCIAL STATEMENTS Document Condensed Interim Consolidated Financial Statements (unaudited) Oncolytics Biotech Inc. For the three months ended

Oncolytics Biotech Inc. reported its condensed interim consolidated financial statements for the quarter ending March 31, 2024. The company faced a net loss of $6,894 thousand, compared to $6,437 thousand for the same quarter in the previous year, contributing to an accumulated deficit of $452,897 thousand. Despite a mild increase in cash and cash equivalents, the operational losses raise concerns about continued financing. The firm plans to pursue funding through various equity arrangements and strategic collaborations to support ongoing clinical trials.

Oncolytics Biotech® Reports First Quarter 2024 Financial Results and Operational Highlights

Oncolytics Biotech reported its Q1 2024 financial results, highlighting significant advancements in its clinical trials. The company has been granted a Type C meeting with the FDA to discuss a registration-enabling study for pelareorep in HR+/HER2- metastatic breast cancer. Positive interim results from the GOBLET study have prompted further patient enrollment in the anal cancer cohort, while also initiating a new pancreatic cancer cohort supported by a $5 million grant from PanCAN. The company's cash reserves of $29.6 million provide a solid foundation for continued research and development efforts.

Oncolytics Biotech reported positive operational highlights and financial results for Q4 and full year 2023, showcasing the advancement of their lead candidate, pelareorep. The company is set to enter a registration-enabling study for pelareorep in pancreatic cancer and plans to report overall survival data from its BRACELET-1 study in 2024. Improvement in response rates for patients in the GOBLET study led to enrollment expansions, while recent data affirmed pelareorep's immunotherapeutic potential. Despite these advancements, the company reported a net loss of $3.9 million for Q4 2023, although this was a decrease from the previous year.

-ONCY

Mar 5, 2024

ONCYPhases

▲ +12%on this newsshared move

Oncolytics Biotech® Files Amendment to Initiate New Pancreatic Cancer GOBLET Cohort Supported by PanCAN

Oncolytics Biotech, Inc. has been awarded a $5 million grant from the Pancreatic Cancer Action Network (PanCAN) to further develop its investigational immunotherapy, pelareorep, for pancreatic cancer. This funding will facilitate clinical trials exploring the combination of pelareorep with modified FOLFIRINOX chemotherapy. The initiative aims to provide new treatment options for pancreatic cancer patients, a disease known for its aggressive nature and high mortality rates. Following the FDA's Fast Track designation of their treatment combination, Oncolytics seeks to improve patient outcomes through innovative therapy approaches.

-ONCY

Sep 19, 2023

ONCYConferences/Events

Oncolytics Biotech® Announces Fireside Chat at the Cantor Global Healthcare Conference

Oncolytics Biotech Inc. announced its participation in the Cantor Global Healthcare Conference 2023, scheduled for September 26-28, where CEO Dr. Matt Coffey will participate in a fireside chat. The company will also engage in one-on-one investor meetings at the conference. A live webcast of the presentation will be accessible on Oncolytics' website, with content archived for three months. The company continues to develop its immunotherapeutic agent, pelareorep, which has shown promising results in cancer treatment.

Oncolytics Biotech® Announces Full Exercise of Over-Allotment Option from Public Offering

Oncolytics Biotech Inc. announced the full exercise of the over-allotment option from their public offering, raising an additional $2,250,112. This was part of a larger offering totaling $15,000,750 aimed at advancing the company's pelareorep clinical programs targeting metastatic breast and pancreatic cancers. The offering is supported by a prospectus filed in multiple Canadian jurisdictions. The underwriter received a commission and compensation warrants as part of the transaction.

-ONCY

Sep 6, 2023

ONCYConferences/Events

Oncolytics Biotech® to Participate in a Fireside Chat at the H.C. Wainwright 25th Annual Global Investment Conference

Oncolytics Biotech Inc. announced that CEO Dr. Matt Coffey will speak at the H.C. Wainwright 25th Annual Global Investment Conference taking place from September 11-13, 2023, in New York. The company will also participate in one-on-one investor meetings and provide a live webcast of the presentation. Oncolytics is known for developing pelareorep, an immunotherapeutic agent aimed at treating various cancers. This event is expected to increase the company's engagement with potential investors.

-ONCY

Aug 14, 2023

ONCYGeneral

Oncolytics Biotech's pelareorep has been chosen for inclusion in the Precision Promise adaptive Phase 3 clinical trial aimed at treating first-line metastatic pancreatic ductal adenocarcinoma. This innovative trial design will reduce the cost and time required for registration by nearly 50%. Previous data has shown a significant improvement in response rates when pelareorep is combined with standard treatment options. The company aims to finalize its agreements and commence the trial in early 2024, providing hope for pancreatic cancer patients facing limited treatment options.

-ONCY

Jun 5, 2023

ONCYPhases

Oncolytics Biotech® Announces Updated Randomized Phase 2 Data from BRACELET-1 Metastatic Breast Cancer Trial that Show Pelareorep Driving Robust Increases in Progression-Free Survival and Confirmed Overall Response Rate

Oncolytics Biotech announced promising updated results from its BRACELET-1 randomized phase 2 trial targeting HR+/HER2- metastatic breast cancer. The trial showed a significant reduction in disease progression risk by 71% and an overall response rate of 37.5% when combining the drug pelareorep with paclitaxel. Additionally, a 12-month progression-free survival rate of 32.8% was reported for the combination treatment. These results position Oncolytics to advance towards a pivotal phase 3 registrational study.

-ONCY

May 26, 2023

ONCYConferences/Events

▼ -19%on this news

Oncolytics Biotech Inc. announced that its abstract detailing the BRACELET-1 trial will be presented orally at the ASCO Annual Meeting on June 3, 2023. The trial focuses on combining the oncolytic reovirus pelareorep with chemotherapy and immunotherapy for HR+/HER2- metastatic breast cancer. CEO Dr. Matt Coffey expressed pride in this opportunity, emphasizing its importance to stakeholders in breast cancer treatment. The data published at ASCO aims to contribute to advancements in this critical area of oncology.

-ONCY

Apr 12, 2023

ONCYGeneral

FDA Fast Track designation granted after presentation at the SITC 37th Annual Meeting demonstrating 69% objective response rate SAN DIEGO, and CALGARY, AB, Dec. 1, 2022 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that the U.S. Food and Drug

-ONCY

Nov 21, 2022

ONCYConferences/Events

Oncolytics Biotech® Announces Presentations at the Upcoming San Antonio Breast Cancer Symposium

SAN DIEGO and CALGARY, AB, Nov. 21, 2022 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced the publication of two abstracts for poster presentations at the upcoming San Antonio Breast Cancer Symposium (SABCS), to be held at the Henry B. González C

Oncolytics Biotech® Presents Updated Clinical Data at SITC Annual Meeting Showing a 69% Objective Response Rate and Confirmed Complete Response in GOBLET Study

One complete response (CR) and eight partial responses (PR) achieved in thirteen evaluable patients 69% objective response rate (ORR) is nearly three times greater than the average ORR of ~25% reported in historical control trials Data support Oncolytics' plan to advance its pa

-ONCY

Nov 7, 2022

ONCYGeneral

▲ +19%on this news· ran to +56% by day 3shared move

Oncolytics Biotech® Reports Third Quarter 2022 Financial Results and Recent Operational Highlights

Clinical interim data reported earlier today from GOBLET trial's pancreatic cancer cohort show an objective response rate (ORR) nearly triple the average ORR seen in relevant historical control trials Pipeline now provides multiple registration opportunities in breast and pancre

-ONCY

Nov 7, 2022

ONCYPhases

▲ +19%on this news· ran to +56% by day 3shared move

Oncolytics Biotech® Reports Interim Results from Phase 1/2 GOBLET Study Showing a 70% Objective Response Rate in Pancreatic Cancer at the SITC Annual Meeting

70% objective response rate (ORR; n=10) is nearly triple the average ORR of ~25% reported in historical control trials1-4 Data suggest pelareorep synergizes with PD-(L)1 inhibitors and standard-of-care chemotherapy in advanced/metastatic pancreatic ductal adenocarcinoma Oncolyt

SAN DIEGO, Calif. and CALGARY, AB, May 10, 2022 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that Dr. Matt Coffey, President and Chief Executive Officer, will participate in a fireside chat at the 2022 RBC Capital Markets Global Healthcare Co

-ONCY

May 5, 2022

ONCYGeneral

Oncolytics Biotech® Announces Publication of Preclinical and Patient Data Demonstrating Pelareorep

SAN DIEGO and CALGARY, AB, March 17, 2022 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced the publication of preclinical and patient data on pelareorep in the peer-reviewed journal Immunology. The paper, entitled "Oncolytic virus treatment diffe

-ONCY

Mar 9, 2022

ONCYPhases

Oncolytics Biotech® Announces Phase 1b Data Demonstrating Clinical Proof-of-Concept for Pelareorep-Proteasome Inhibitor Combination in Multiple Myeloma in an Abstract at the AACR Annual Meeting

- Prolonged progression-free survival of >3 years achieved in a subset of relapsed/refractory patients - Treatment-induced increases in tumor-infiltrating anti-cancer immune cells correlated with clinical response SAN DIEGO, Calif. and CALGARY, AB, March 9, 2022 /PRNewswire/ --

-ONCY

Mar 9, 2022

ONCYConferences/Events

Oncolytics Biotech® Announces Upcoming Poster Presentation at the AACR Annual Meeting

SAN DIEGO, Calif. and CALGARY, AB, March 9, 2022 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced an upcoming poster presentation that will feature long-term follow-up results from ReoGlio, an investigator-sponsored, phase 1b trial evaluating the

Oncolytics Biotech® Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Operational Highlights

Randomized phase 2 metastatic breast cancer trial (BRACELET-1) on track for top-line data in Q4 2022 Clinical breast cancer data indicate pelareorep-induced changes in blood T cell populations may be a predictive biomarker – a key finding for de-risking a phase 3 registrational

-ONCY

Feb 2, 2022

ONCYPhases

Oncolytics Biotech announced an abstract for the ASH Annual Meeting, highlighting pelareorep's potential to increase PD-L1 expression when combined with carfilzomib in myeloma patients. The study showed promising clinical responses, indicating pelareorep's role as a candidate for combination therapies with immune checkpoint inhibitors. The full details will be presented at the conference.

News release via Canada NewsWire, Toronto 416-863-9350 Attention Business Editors: Oncolytics Biotech Inc. Announces Issuance of 31st U.S. Patent CALGARY, Jan. 13 /CNW/ - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) ("Oncolytics") today announced that it has been granted

Competitive Position

How ONCY ranks across every disease it competes in

Competitive Position is a premium feature

See how ONCY ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.

Start free trial

FDA Calendar

BPW Portfolio

Historical FDA Calendar

Market Movers

Biotech Earning Calendar

Historical PDUFA Dates

PDUFA Calendar

Conference Calendar

IPO

Catalyst Sync™

Hedge Fund Screener

Company Screener

All Stocks Holdings

Heat-Map

Inside Trades

M&A Tracker

News

Blogs

Modality Leaderboard

API

Discord

User Guide

Biotech Investing 101

Recent Updates

Recently added Catalysts

Oncolytics Biotech Inc.

$0.84

Cash Data

Overview

Company Description

Upcoming Catalyst

Catalyst Timeline

Upcoming catalysts 2

Event history 2

Past FDA Catalysts & PDUFA Decisions

Drug Pipeline Intelligence

Clinical Trial Results

Inside Trades

Hedge Funds

Hedge Funds invested in ONCY

ONCY Institutional Ownership Trends

Option Chain Statistics

Option Chain

Open interest

Option Volume

Company News

Oncolytics Biotech® Aligns with FDA on Registrational Path for Second-Line RAS-Mutant MSS Colorectal Cancer

Oncolytics Biotech® Receives Fast Track Designation for Pelareorep in Second-Line and Later Anal Cancer

Oncolytics Biotech® Reports FDA Regulatory Milestone and Strong Clinical Progress in Randomized RAS-Mutant MSS Colorectal Cancer Trial

Oncolytics Biotech® Secures New U.S. Patent Protecting Commercial Manufacturing of Pelareorep into 2044

Oncolytics Biotech® Announces Appointment of Steve Glover to Board of Directors and Promotion of John McAdory to Chief Operating Officer

Oncolytics Biotech Announces Positive Initial Preclinical Findings Supporting Further Evaluation of Pelareorep in Combination with RAS-Targeted Approaches

Oncolytics Biotech® to Present Data at ASCO 2026 Reinforcing Pelareorep’s Potential Across Gastrointestinal Tumors

Oncolytics Biotech® Reports Durable Responses in Second-Line RAS-Mutant MSS Colorectal Cancer

Oncolytics Aligns with FDA on Planned Pivotal Anal Cancer Study

Oncolytics Biotech® Announces Type C FDA Meeting to Discuss Single-arm Registrational Pathway for Pelareorep in Anal Cancer

Oncolytics Biotech® Completes Domicile Change to the United States

Oncolytics Biotech to Present New Mechanistic and Translational Data Supporting Pelareorep as an Immune-Priming Backbone at AACR 2026

Oncolytics Biotech® Launches Randomized Colorectal Cancer Study

Immuno-Oncology Investments Accelerate as Pipeline Catalysts Multiply in 2026

Oncolytics Biotech® to Prioritize Registration-Focused Programs in Anal and Colorectal Cancer

The $71 Billion Cancer Shift: Why The FDA Is Speeding Up

Oncolytics Biotech® Receives FDA Fast Track Designation for Pelareorep in 2L KRAS-Mutant MSS Metastatic Colorectal Cancer

Oncolytics Biotech® Announces Results of Special Meeting of Shareholders

Oncolytics Biotech® Appoints John McAdory as EVP of Strategy and Operations and Yujun Wu to Lead Biostatistics

Oncolytics Biotech® Announces Updated Clinical Data from GOBLET Cohort 4 Demonstrating Activity of Pelareorep Plus Atezolizumab in Third-Line Anal Cancer

Oncolytics Biotech® Outlines Strategic Rationale for Proposal to Change Jurisdiction of Incorporation to Nevada

Oncolytics Biotech® Provides Update on Intellectual Property Strategy and Patent Filings

THIRD QUARTER INTERIM FINANCIAL STATEMENTS Document Condensed Interim Consolidated Financial Statements (unaudited) Oncolytics Biotech Inc. For the three and nine months ended

Oncolytics Biotech® Reports Updated Anal Cancer Data Showing Objective Response Rate More Than Double the Current Standard of Care

Oncolytics Biotech® Files Circular/Prospectus for Special Meeting of Shareholders To Change Jurisdiction of Incorporation to Nevada

Forward-Looking Statements Overview Neither the Securities and Exchange Commission nor any state or foreign securities commission or regulatory authority has passed upon the adequacy or accuracy of this presentation. Any

Oncolytics Biotech® Announces Update for Potential First-Line Pancreatic Cancer Registration Study

Oncolytics Biotech® Provides Update on GOBLET Study Progress and U.S. Site Expansion

Oncolytics Biotech® Highlights Strong Efficacy and Translational Data in Metastatic Colorectal Cancer; Will Advance Regulatory Pathway Discussions

Oncolytics Biotech® Provides Updated Clinical Safety Data for Pelareorep, Including Across Multiple Gastrointestinal Tumors

Oncolytics Biotech® Announces Upcoming Investor Conferences in September

Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders

Oncolytics Biotech® Announces Voluntary Delisting from the Toronto Stock Exchange

Oncolytics Biotech® Reports Second Quarter Financial Results and Details Clinical Program Plans for Pelareorep